Proteomic differences in brain vessels of Alzheimer’s disease mice : normalization by PPARγ agonist pioglitazone

From National Research Council Canada

DOIResolve DOI: https://doi.org/10.1177/0271678X16655172
AuthorSearch for: ; Search for: 1; Search for: 1; Search for: 1; Search for:
Name affiliation
  1. National Research Council Canada. Human Health Therapeutics
FormatText
TypeArticle
Journal titleJournal of Cerebral Blood Flow & Metabolism
ISSN0271-678X
1559-7016
Pages1–17
SubjectAmyloid peptide; cerebral artery; oxidative stress; proliferator-activated receptor gamma; vascular biomarkers
Abstract
Cerebrovascular insufficiency appears years prior to clinical symptoms in Alzheimer’s disease. The soluble, highly toxic amyloid-β species, generated from the amyloidogenic processing of amyloid precursor protein, are known instigators of the chronic cerebrovascular insufficiency observed in both Alzheimer’s disease patients and transgenic mouse models. We have previously demonstrated that pioglitazone potently reverses cerebrovascular impairments in a mouse model of Alzheimer’s disease overexpressing amyloid-β. In this study, we sought to characterize the effects of amyloid-β overproduction on the cerebrovascular proteome; determine how pioglitazone treatment affected the altered proteome; and analyze the relationship between normalized protein levels and recovery of cerebrovascular function. Three-month-old wildtype and amyloid precursor protein mice were treated with pioglitazone- (20 mg/kg/day, 14 weeks) or control-diet. Cerebral arteries were surgically isolated, and extracted proteins analyzed by gel-free and gel-based mass spectrometry. 193 cerebrovascular proteins were abnormally expressed in amyloid precursor protein mice. Pioglitazone treatment rescued a third of these proteins, mainly those associated with oxidative stress, promotion of cerebrovascular vasocontractile tone, and vascular compliance. Our results demonstrate that amyloid-β overproduction perturbs the cerebrovascular proteome. Recovery of cerebrovascular function with pioglitazone is associated with normalized levels of key proteins in brain vessel function, suggesting that pioglitazone-responsive cerebrovascular proteins could be early biomarkers of Alzheimer’s disease.
Publication date
Noteyes
LanguageEnglish
Peer reviewedYes
NPARC number23000685
Export citationExport as RIS
Report a correctionReport a correction
Record identifier71d738d5-c813-45cd-a157-dd851d4d9558
Record created2016-08-23
Record modified2020-03-16
Report a problem on this page
Date modified: